CAMBRIDGE, Mass.--(BUSINESS WIRE)--Feb 6, 2020--

Cadent Therapeutics, a clinical stage biopharmaceutical company focused on the development of therapies to improve the lives of patients with movement, mood, and cognitive disorders, today announced that the Company's Cadence-1 study will be highlighted in a poster presentation at the 3 rd Pan American Parkinson’s Disease and Movement Disorders Congress from February 14-16, 2020 at the InterContinental Miami in Miami, Florida.

The poster, titled “ Phase 2a Open-Label Study to Evaluate the Safety, Tolerability and Efficacy of CAD-1883 in Essential Tremor (Cadence-1),” will be presented on Saturday, February 15, 2020, from 1:00 PM to 2:30 PM in the Biscayne Ballroom at the InterContinental Miami.

About Cadent Therapeutics

Cadent Therapeutics is creating therapies for the treatment of movement, mood, and cognitive disorders. The company combines target specificity, patient selection, drug design and optimization, and novel quantitative endpoints to create first-in-class molecules to treat movement and cognitive disorders. Cadent Therapeutics is rapidly advancing its pipeline of positive allosteric modulators to treat spinocerebellar ataxia, essential tremor, and schizophrenia. The company has an exclusive license and collaboration agreement with Novartis to develop a negative allosteric modulator, now in Phase 2 for the treatment of treatment resistant depression. Investors include Atlas Venture, Cowen Healthcare Investments, Qiming Venture Partners, Access Industries, Clal Biotechnology Industries, Novartis Corporate and Slater Technology Fund. For more information, please visit cadenttx.com.

CONTACT: Investors:

Maeve Conneighton,maeve@argotpartners.com

212.600.1902Media:

David Rosen,david.rosen@argotpartners.com

212.600.1902

KEYWORD: MASSACHUSETTS UNITED STATES NORTH AMERICA

INDUSTRY KEYWORD: BIOTECHNOLOGY MENTAL HEALTH HEALTH PHARMACEUTICAL CLINICAL TRIALS

SOURCE: Cadent Therapeutics

Copyright Business Wire 2020.

PUB: 02/06/2020 04:05 PM/DISC: 02/06/2020 04:05 PM

Copyright Business Wire 2020.

Welcome to the discussion.

Keep it Clean. Please avoid obscene, vulgar, lewd, racist or sexually-oriented language.
PLEASE TURN OFF YOUR CAPS LOCK.
Don't Threaten. Threats of harming another person will not be tolerated.
Be Truthful. Don't knowingly lie about anyone or anything.
Be Nice. No racism, sexism or any sort of -ism that is degrading to another person.
Be Proactive. Use the 'Report' link on each comment to let us know of abusive posts.
Share with Us. We'd love to hear eyewitness accounts, the history behind an article.

PLEASE BE ADVISED: Soon we will no longer integrate with Facebook for story comments. The commenting option is not going away, however, readers will need to register for a FREE site account to continue sharing their thoughts and feedback on stories. If you already have an account (i.e. current subscribers, posting in obituary guestbooks, for submitting community events), you may use that login, otherwise, you will be prompted to create a new account.

Load comments